Angamuthu Selvapandiyan | Professor
Jamia Hamdard
Dr. A. Selvapandiyan has been a prominent figure in vaccine development, with over 35 years of experience post-Ph.D. in molecular biology, focusing on molecular cell biology, diagnostics, immunology, and vaccinology. He has served as a Senior Research Scientist at the International Centre for Genetic Engineering and Biotechnology (UNIDO organization) in Delhi (1988-1999), a Visiting Scientist at the FDA USA (1999-2009), and as Team Lead and Professor (currently) at the Department of Molecular Medicine, Jamia Hamdard, Delhi. A significant achievement includes developing a gene-deleted live attenuated vaccine against visceral leishmaniasis, a severe parasitic disease, during his time at the US FDA. Since then, this vaccine candidate has undergone numerous experimental and preclinical studies in animals, with findings published in journals and protected by patents. Having successfully passed animal toxicity studies, the vaccine is poised to progress beyond the concept stage, demonstrating Dr. Selvapandiyan's substantial impact on vaccine innovation.
Appearances:
Pre-Congress Workshops - 21st April @ 14:00
GLOBAL HEALTH - PARASITIC & NTD VACCINES
2.10pm – 3.10pm Parasitic disease vaccine development short talks:
4x 15min presentations
2.10pm Hookworm anaemia and malaria combination vaccine development
Dr Peter Hotez, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine
2.25pm Early development of a vaccine against visceral leishmaniasis * Title TBC
Dr Angamuthu Selvapandiyan, Professor, Department of Molecular Medicine, School of Interdisciplinary Studies and Technology, JAMIA HAMDARD
2.40pm Joint Presentation: A defined molecular vaccine for intestinal schistosomiasis * title TBC
Darrick Carter, CEO, PAI LifesciencesAfzal Siddiqui, Professor, Department of Internal Medicine, Professor (Tenured), Departments of Internal Medicine and Immunology & Molecular Immunology, Texas Tech University Health Sciences Center
2.55pm Development of vaccines for lymphatic filariasis *Title TBC
Dr Ramaswamy Kalyanasundaram, Department Head, Professor of Microbiology and Immunology, University of Illinois College of Medicine
3.10pm Panel: Challenges in establishing correlates of protection and planning trials for NTD vaccines
· What are the difficulties in establishing COP for NTD vaccines
· Planning for ph2-3 trials – how can we innovate in creating pathways and designs?
Darrick Carter, CEO, PAI Lifesciences
Afzal Siddiqui, Professor, Department of Internal Medicine, Professor (Tenured), Departments of Internal Medicine and Immunology & Molecular Immunology, Texas Tech University Health Sciences Center
Dr Ramaswamy Kalyanasundaram, Department Head, Professor of Microbiology and Immunology, University of Illinois College of Medicine
Michael, Senior Director, Principal Consultant DCS/BPE, Cencora
Additional panelists TBC
4.00pm Panel: Moving the needle: alternative pathways to approval for global health vaccines (Parasitic & Neglected Diseases)
· Considering pathways to approval in different scenarios – in-country experiences
o Enabling different technology pathways
o From a local manufacturing perspective
· Moving from science to deployment – other than strong data what do we need to move these vaccines forward?
o Understanding incentives for production, government incentives to buy, individual country policies and regulatory requirements
o How is this challenge further compounded with diseases that are not fatal but have high morbidity burden?
o Case studies – Marburg, Hookworm,
· Improving stringency of regulatory agencies through new frameworks
· Can combinations deal with the issue of high burden but low interest? What would be the complications of combining these types of vaccines?
Dr Maria Elena Bottazzi, Co-Director of Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine
Dr Kelly Warfield, President of Global Research, Sabin Vaccine Institute
Javier Guzman, Director of Global Health Policy and Senior Fellow, Center for Global Development
Petro Terblanche, Managing Director, Afrigen
Prof Tuck Seng Wong, Professor, Sheffield University; Director, UKSEA Vax Hub
Dr William Hausdorff, Public Health Value Proposition Lead, PATH
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events